Phase 1 Age-Related Macular Degeneration Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular Degeneration
AbbVie66 enrolled4 locationsNCT07160179
Recruiting
Phase 1Phase 2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Geographic AtrophyDry Age-Related Macular Degeneration
National Eye Institute (NEI)20 enrolled2 locationsNCT04339764
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting
Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-Related Macular Degeneration
Astellas Institute for Regenerative Medicine42 enrolled19 locationsNCT03178149
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 1Phase 2
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458
Recruiting
Phase 1
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting
Phase 1
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Age-Related Macular Degeneration
Benobio Co., Ltd.18 enrolled2 locationsNCT05803785
Recruiting
Phase 1Phase 2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.68 enrolled9 locationsNCT05986864
Recruiting
Phase 1
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Youxin Chen12 enrolled3 locationsNCT06213038
Recruiting
Phase 1Phase 2
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Age-Related Macular Degeneration
Chengdu Origen Biotechnology Co., Ltd.42 enrolled1 locationNCT05672121
Recruiting
Phase 1Phase 2
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd.48 enrolled1 locationNCT06141460
Recruiting
Phase 1Phase 2
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Recruiting
Phase 1Phase 2
Gene Therapy(FT-003) for Wet AMD
Neovascular Age-related Macular Degeneration
Frontera Therapeutics78 enrolled1 locationNCT06492863
Completed
Phase 1
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 696844 Administered Subcutaneously to Healthy Volunteers
Age-Related Macular Degeneration
Ionis Pharmaceuticals, Inc.30 enrolled2 locationsACTRN12616000335493